Nucleic Acids Research, 2002, Vol. 30, No. 4 958-965
© 2002 Oxford University Press
The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation
Department of Genetics and 1Department of Microbiology, University of Erlangen, Staudtstrasse 5, 91058 Erlangen, Germany
Alterations of the proto-oncogene MLL (mixed lineage leukemia) are characteristic for a high proportion of acute leukemias, especially those occurring in infants. The activation of MLL is achieved either by an internal tandem duplication of 5' MLL exons or by chromosomal translocations that create chimeric proteins with the N-terminus of MLL fused to a variety of different partner proteins. A domain of MLL with significant homology to the eukaryotic DNA methyltransferases (MT domain) has been found to be essential for the transforming potential of the oncogenic MLL derivatives. Here we demonstrate that this domain specifically recognizes DNA with unmethylated CpG sequences. In gel mobility shifts, the presence of CpG was sufficient for binding of recombinant GST–MT protein to DNA. The introduction of 5-methylCpG on one or both DNA strands precluded an efficient interaction. In surface plasmon resonance a KD of 
3.3 x 10–8 M was determined for the GST–MT/DNA complex formation. Site selection experiments and DNase I footprinting confirmed CpG as the target of the MT domain. Finally, this interaction was corroborated in vivo in reporter assays utilizing the DNA-binding properties of the MT domain in a hybrid MT–VP16 transactivator construct.
* To whom correspondence should be addressed. Tel: +49 9131 8528527; Fax: +49 9131 8528526; Email: rslany{at}biologie.uni-erlangen.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. E. Erfurth, R. Popovic, J. Grembecka, T. Cierpicki, C. Theisler, Z.-B. Xia, T. Stuart, M. O. Diaz, J. H. Bushweller, and N. J. Zeleznik-Le MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression PNAS, May 27, 2008; 105(21): 7517 - 7522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Claus, M. Fliegauf, M. Stock, J. A. Duque, M. Kolanczyk, and M. Lubbert Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression J. Leukoc. Biol., December 1, 2006; 80(6): 1462 - 1472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Gearhart, C. M. Corcoran, J. A. Wamstad, and V. J. Bardwell Polycomb Group and SCF Ubiquitin Ligases Are Found in a Novel BCOR Complex That Is Recruited to BCL6 Targets. Mol. Cell. Biol., September 1, 2006; 26(18): 6880 - 6889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Terranova, H. Agherbi, A. Boned, S. Meresse, and M. Djabali Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll PNAS, April 25, 2006; 103(17): 6629 - 6634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Slany Chromatin control of gene expression: Mixed-lineage leukemia methyltransferase SETs the stage for transcription PNAS, October 11, 2005; 102(41): 14481 - 14482. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Milne, Y. Dou, M. E. Martin, H. W. Brock, R. G. Roeder, and J. L. Hess From The Cover: MLL associates specifically with a subset of transcriptionally active target genes PNAS, October 11, 2005; 102(41): 14765 - 14770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-B. Xia, R. Popovic, J. Chen, C. Theisler, T. Stuart, D. A. Santillan, F. Erfurth, M. O. Diaz, and N. J. Zeleznik-Le The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression PNAS, September 27, 2005; 102(39): 14028 - 14033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Whitman, S. Liu, T. Vukosavljevic, L. J. Rush, L. Yu, C. Liu, M. I. Klisovic, K. Maharry, M. Guimond, M. P. Strout, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy Blood, July 1, 2005; 106(1): 345 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ayton, E. H. Chen, and M. L. Cleary Binding to Nonmethylated CpG DNA Is Essential for Target Recognition, Transactivation, and Myeloid Transformation by an MLL Oncoprotein Mol. Cell. Biol., December 1, 2004; 24(23): 10470 - 10478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. F. Jorgensen, I. Ben-Porath, and A. P. Bird Mbd1 Is Recruited to both Methylated and Nonmethylated CpGs via Distinct DNA Binding Domains Mol. Cell. Biol., April 15, 2004; 24(8): 3387 - 3395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-W. Deng, I. Chiu, and J. L. Strominger MLL 5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression PNAS, January 20, 2004; 101(3): 757 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B. Zeisig, T. Milne, M.-P. Garcia-Cuellar, S. Schreiner, M.-E. Martin, U. Fuchs, A. Borkhardt, S. K. Chanda, J. Walker, R. Soden, et al. Hoxa9 and Meis1 Are Key Targets for MLL-ENL-Mediated Cellular Immortalization Mol. Cell. Biol., January 15, 2004; 24(2): 617 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-B. Xia, M. Anderson, M. O. Diaz, and N. J. Zeleznik-Le MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein PNAS, July 8, 2003; 100(14): 8342 - 8347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yokoyama, I. Kitabayashi, P. M. Ayton, M. L. Cleary, and M. Ohki Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties Blood, November 15, 2002; 100(10): 3710 - 3718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Lee and D. G. Skalnik CpG-binding Protein Is a Nuclear Matrix- and Euchromatin-associated Protein Localized to Nuclear Speckles Containing Human Trithorax. IDENTIFICATION OF NUCLEAR MATRIX TARGETING SIGNALS J. Biol. Chem., October 25, 2002; 277(44): 42259 - 42267. [Abstract] [Full Text] [PDF]
|
|